Lundbeck shares swell on positive results for dementia drug

H Lundbeck A/S

27/06/2022 08:22

** Shares in Lundbeck  HLUNb.CO  rise 7.5% after the Danish
drugmaker and Japan's Otsuka Pharmaceutical  4768.T  announce
positive Phase III results for brexpiprazole drug used to treat
agitation in patients with Alzheimer's-type dementia
 urn:newsml:reuters.com:*:nL8N2YE118
     ** The companies are planning a regulatory filing to the
U.S. Food and Drug Administration later in 2022
    ** The announcement is the second good news this year, Per
Hansen from Nordnet says; the first was the positive surprise in
Q1 results, where an upward revision was probably only thwarted
by the shutdown in China, he adds
    ** Monday's gains add 2.5 billion Danish crowns ($355.27
million) to the company's market cap

($1 = 7.0370 Danish crowns)

 (Reporting by Agnieszka Gosciak)
 ((agnieszka.gosciak@thomsonreuters.com))